Press coverage about Aerie Pharmaceuticals (NASDAQ:AERI) has trended somewhat positive recently, according to Accern Sentiment. The research firm identifies positive and negative media coverage by reviewing more than twenty million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Aerie Pharmaceuticals earned a news sentiment score of 0.15 on Accern’s scale. Accern also gave headlines about the company an impact score of 46.0518647624259 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.

These are some of the news headlines that may have effected Accern Sentiment Analysis’s rankings:

Aerie Pharmaceuticals (AERI) opened at 58.30 on Friday. Aerie Pharmaceuticals has a 52 week low of $32.05 and a 52 week high of $60.15. The stock’s market cap is $2.12 billion. The company has a 50 day moving average price of $54.57 and a 200 day moving average price of $49.84.

Aerie Pharmaceuticals (NASDAQ:AERI) last posted its quarterly earnings results on Tuesday, August 1st. The company reported ($0.82) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.84) by $0.02. Analysts expect that Aerie Pharmaceuticals will post ($2.59) EPS for the current fiscal year.

A number of equities analysts have weighed in on the company. Cantor Fitzgerald reiterated an “overweight” rating and set a $62.00 price objective (up previously from $56.00) on shares of Aerie Pharmaceuticals in a research note on Thursday, July 20th. Aegis lifted their price objective on Aerie Pharmaceuticals from $63.00 to $70.00 and gave the company a “buy” rating in a research note on Thursday, May 25th. Needham & Company LLC reiterated a “buy” rating and set a $65.00 price objective on shares of Aerie Pharmaceuticals in a research note on Sunday. HC Wainwright reiterated a “buy” rating and set a $69.00 price objective on shares of Aerie Pharmaceuticals in a research note on Thursday, May 25th. Finally, Cowen and Company set a $100.00 price objective on Aerie Pharmaceuticals and gave the company a “buy” rating in a research note on Friday, May 26th. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and twelve have issued a buy rating to the stock. The company presently has an average rating of “Buy” and an average price target of $66.36.

ILLEGAL ACTIVITY NOTICE: “Somewhat Favorable News Coverage Somewhat Unlikely to Affect Aerie Pharmaceuticals (AERI) Share Price” was first posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this report on another publication, it was stolen and reposted in violation of international trademark & copyright law. The correct version of this report can be read at https://www.thecerbatgem.com/2017/09/17/somewhat-favorable-news-coverage-somewhat-unlikely-to-affect-aerie-pharmaceuticals-aeri-share-price.html.

Aerie Pharmaceuticals Company Profile

Aerie Pharmaceuticals, Inc is a clinical-stage pharmaceutical company. The Company is engaged in the discovery, development and commercialization of therapies for the treatment of patients with glaucoma and other diseases of the eye. The Company’s product candidates include Rhopressa (netarsudil ophthalmic solution) 0.02% (Rhopressa), and Roclatan (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005% (Roclatan).

Insider Buying and Selling by Quarter for Aerie Pharmaceuticals (NASDAQ:AERI)

Receive News & Stock Ratings for Aerie Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aerie Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.